UNSPSC 51162650: Xyloxemine

This classification denotes an antitussive agent with the molecular formula C23H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L95KV83PV9, chemically known as 2-(2-(di-2,6-xylylmethoxy)ethoxy)-n,n-dimethylethylamine but more generally known as xyloxemine, which bears US NIH Compound Identifier 17800. European Medicines Agency schedules Xyloxemine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00123MIG. The term XYLOXEMINE is an International Non-Proprietary Name.

UNSPSC 51162650 Xyloxemine (Commodity) addresses pharmaceutical products and drug-related medical supplies that state and local governments procure for public health, community health, and emergency response initiatives. Recent solicitations show state and local buyers acquiring naloxone (a critical opioid-overdose reversal medication) and safe drug deactivation systems for community health programs, as well as generic multi-source pharmaceuticals and over-the-counter products for distribution through state and local health facilities. Issuing bodies include county health departments, state multistate cooperative purchasing alliances, and health system facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as a repeat buyer aggregating demand across participating state and local government facilities including Oregon.

Recent activity centers in Florida and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the procurement included shipping and delivery costs and a two-year initial term with one-year renewal option. MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, requiring vendor compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and pricing weighted 75 percent on competitiveness, with awarded vendors effective July 1, 2026.